Results
|
|
21.
|
|
|
|
22.
|
|
|
|
23.
|
|
|
|
24.
|
|
|
|
25.
|
|
|
|
26.
|
|
|
|
27.
|
|
|
|
28.
|
|
|
|
29.
|
|
|
|
30.
|
|
|
|
31.
|
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. [electronic resource] by
- Boss, D S
- Witteveen, P O
- van der Sar, J
- Lolkema, M P
- Voest, E E
- Stockman, P K
- Ataman, O
- Wilson, D
- Das, S
- Schellens, J H
Producer: 20110502
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 22
Availability: No items available.
|
|
|
32.
|
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. [electronic resource] by
- Boss, D S
- Glen, H
- Beijnen, J H
- Keesen, M
- Morrison, R
- Tait, B
- Copalu, W
- Mazur, A
- Wanders, J
- O'Brien, J P
- Schellens, J H M
- Evans, T R J
Producer: 20120720
In:
British journal of cancer vol. 106
Availability: No items available.
|
|
|
33.
|
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. [electronic resource] by
- van der Noll, R
- Smit, W M
- Wymenga, A N M
- Boss, D S
- Grob, M
- Huitema, A D R
- Rosing, H
- Tibben, M M
- Keessen, M
- Rehorst, H
- Beijnen, J H
- Schellens, J H M
Producer: 20160912
In:
Investigational new drugs vol. 33
Availability: No items available.
|
|
|
34.
|
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. [electronic resource] by
- Boss, D S
- Schwartz, G K
- Middleton, M R
- Amakye, D D
- Swaisland, H
- Midgley, R S
- Ranson, M
- Danson, S
- Calvert, H
- Plummer, R
- Morris, C
- Carvajal, R D
- Chirieac, L R
- Schellens, J H M
- Shapiro, G I
Producer: 20100622
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 21
Availability: No items available.
|